Earnings ·
Reports Q3 net loss of $18.7M on higher R&D costs; holds $244.5M cash
CTNMContineum Therapeutics, Inc.
Contineum Therapeutics reported a third-quarter 2026 net loss of $18.7 million, compared to $12.8 million in the prior-year period. Research and development expenses rose 45 percent to $16.0 million, driven by costs for the PIPE-791 idiopathic pulmonary fibrosis program, while general and administrative expenses increased 26 percent to $5.0 million due to higher stock-based compensation. The company ended the quarter with $244.5 million in cash, equivalents, and marketable securities, projecting a runway through mid-2029. Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies for inflammatory and fibrotic diseases.